Aenitis Technologies
Philippe Tramoy is a seasoned partner at Seventure Partners since November 2013, where involvement centers around the Quadrivium Fund, which finances start-ups in Digital technologies and Life sciences linked to prominent academic institutions. Additionally, Tramoy holds board member positions at several biotechnology firms, including CryoCapCell, PEP-Therapy, and Aenitis Technologies, focusing on innovative solutions in electron microscopy, targeted cancer therapies, and fluid component separation. Past board memberships also include roles at Scipio Bioscience, myBrain Technologies, Keen Eye Technologies, MilliDrop, DIABNEXT, and horseCom. Educational credentials include multiple Master's degrees in Marketing, Finance, Immunology & Molecular Biology, and Biochemistry from renowned institutions such as HEC Paris and École normale supérieure de Lyon.
This person is not in any teams
Aenitis Technologies
1 followers
Aenitis Technologies is a spin-off of the Centre National de la Recherche Scientifique (CNRS) and the Laboratory of Physics and Mechanics of Heterogeneous Environments (PMMH) of the Graduate School of Industrial Physics and Chemistry of the City of Paris (ESPCI) specializing in developing innovative solutions for separation, handling and filtration of biological particles in suspension or not based on acoustophoresis technologies. The company initially focused on medical issues where its technological solutions bring innovation breaks with current practices.